ReviewFrontiers in cellular neuroscience2025
MAP2 phosphorylation: mechanisms, functional consequences, and emerging insights.
Review in Frontiers in cellular neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- KLF2 Is Associated with ERK1/2-MAP2 Activation and Neuron-like Phenotypic Remodeling of PDGFR-β-Lineage Cells Following Ischemic Stroke.Brain sciences · 2026Article
- Neural stem cell extracellular vesicle-mediated delivery of astragaloside IV attenuates hypoxic-ischemic brain damage by activating the mTOR pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Microtubules in Spinal Cord Injury: From Cytoskeletal Dysregulation to Therapeutic Regeneration.Journal of neurochemistry · 2026Review
- SNAP47 Silencing Impairs the Morphology and Neurotransmission of Hippocampal GABAergic Neurons.Molecular neurobiology · 2026Article
- Review
- CaMKII as a Multimodal Signalling Hub in Neural Connectivity and Vulnerability.Molecular neurobiology · 2026Review
- Association ofFrontiers in psychiatry · 2026Article
- LUHMES-derived 3D organoids as an enhanced platform for modelling dopaminergic neurodegeneration in Parkinson's disease.Frontiers in molecular biosciences · 2026Article
- From Microbiota to Metabolomics: HowNutrients · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Microtubule-associated protein 2 (MAP2) is a key regulator of cytoskeletal dynamics and neuronal function. It stabilizes microtubules, shapes dendrites, influences synaptic plasticity, and regulates transportation and protein synthesis through its interactions with other proteins. MAP2 undergoes extensive phosphorylation, which dynamically modulates these interactions and alters MAP2 functions. This review provides a comprehensive overview of MAP2 structure, its diverse functional roles in neurons, the kinases that regulate its phosphorylation. We highlight how phosphorylation by Src family kinases, proline-directed kinases, MARK, PKA, PKC, and CAMKII governs MAP2's role in cytoskeletal organization, protein chaperone activity, and dendrite outgrowth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.